Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Physician Experience Predicts HIV-Related Mortality

September 1, 2002
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 9
Volume 11
Issue 9

SEATTLE-The number of HIV-infected patients that a physician has treated independently predicts HIV-related mortality in patients starting anti-retroviral therapy for the first time, Robert S. Hogg, PhD, said at the 9th Conference on Retroviruses and Opportunistic Infections (abstract 749W).

SEATTLE—The number of HIV-infected patients that a physician has treated independently predicts HIV-related mortality in patients starting anti-retroviral therapy for the first time,
Robert S. Hogg, PhD, said at the 9th Conference on Retroviruses and Opportunistic Infections (abstract 749W).

Dr. Hogg is program director of population health, British Columbia Centre for Excellence in HIV/AIDS, and associate professor of health care and epidemiology, University of British Columbia, Vancouver.

Dr. Hogg and his colleagues analyzed determinants of HIV-related and all-cause mortality in 1,219 HIV-infected, antiretroviral-naïve patients who were first prescribed triple-drug therapy between August 1996 and September 1999. Data for the patients and their approximately 100 treating physicians were obtained from the database of the British Columbia HIV/AIDS Drug Treatment Program.

Physician experience was assessed from the cumulative number of HIV-infected patients treated and was classified as above or below first quartile. Adherence to therapy was expressed as the number of months of medication dispensed divided by the number of months of follow-up during the first year of therapy, and was classified as intermittent if the value was less than 75%.

During an approximate 30-month follow-up, the rates of HIV-related and all-cause mortality were 6.7% and 8.5%, respectively. All of the non-HIV-related deaths were either suicides or accidental drug overdoses. At the start of the study, the median number of HIV-infected patients previously treated by the physicians was 47 (interquartile range, 7 to 133).

In multivariate analysis of HIV-related mortality, the risk of death was significantly decreased with physician experience above the first quartile (risk ratio, 0.54) and significantly increased with intermittent adherence (risk ratio, 3.83) and CD4 cell count below 200/µL (risk ratios at 50 to 199/µL and less than 50/µL, 3.61 and 7.29, respectively).

In multivariate analysis of all-cause mortality, the risk of death was significantly increased with intermittent adherence (risk ratio, 3.19) and CD4 cell count below 200/µL (risk ratios at 50 to 199/µL and less than 50/µL, 2.25 and 4.96, respectively). However, physician experience was not a significant predictor of all-cause mortality.

"The lack of an association between physician experience and all-cause mortality likely relates to confounding with unmeasured sociodemographic characteristics as well as to the sudden nature of accidental and overdose deaths," Dr. Hogg noted.

Use of protease inhibitors, a diagnosis of AIDS before enrollment, and a baseline plasma viral RNA level greater than 100,000 copies/mL were not significant predictors of either HIV-related or all-cause mortality in multivariate analysis.

The findings identify physician experience, intermittent adherence, and CD4 cell count as strong determinants of mortality in HIV-infected patients in the general population who are starting anti-retroviral therapy, Dr. Hogg said.

"Clearly, researchers must be cognizant of relationships like these prior to building models of prognostic factors associated with disease progression," he concluded.

Articles in this issue

Tumor-Specific Idiotype Vaccines Promising in B-Cell Lymphomas
Childhood Survivors May Not Know Their Past Rx
Pemetrexed/Gemcitabine Promising in Advanced Pancreatic Cancer
Physician Experience Predicts HIV-Related Mortality
Preliminary Phase III Results for Provenge Vaccine in Prostate Cancer
Eloxatin With 5-FU/LV Approved for Recurrent Colon Cancer
Comprehensive Geriatric Evaluations Improve Care
Nordion’s Monte Carlo Dose Calculation Software Approved
No Strong Link Between Breast Cancer Risk and Pollutants
Imatinib Inactive in Sarcomas That Lack C-KIT/PDGF
Task Force Recommends Screening for All Age 50 and Over
No Link Between Breast Cancer Risk and Pollutants
NIH, Drug Industry Target Barriers to Patient Accrual in Clinical Trials
Medicare Puts PET for Thyroid Cancer, Soft Tissue Sarcoma on Hold
Cranial Radiotherapy for Childhood ALL Linked to Adult Obesity
Recent Videos
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
Advertisement

At a median time to response of 1 month, isatuximab elicited a median duration of response of 10.3 months in patients with multiple myeloma.

Isatuximab Shows Efficacy, Acceptable Safety Across Multiple Myeloma Trials

Roman Fabbricatore
May 30th 2025
Article

At a median time to response of 1 month, isatuximab elicited a median duration of response of 10.3 months in patients with multiple myeloma.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Rhenium Obisbemeda Improves Survival in Recurrent Glioblastoma

Rhenium Obisbemeda Improves Survival in Recurrent Glioblastoma

Ariana Pelosci
May 30th 2025
Article

Andrew Brenner, MD, PhD, discussed rhenium obisbemeda and results from the ReSPECT-GBM trial for patients with glioblastoma.


Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Viviana Cortiana, MS4;Yan Leyfman, MD
May 19th 2025
Podcast

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.


Combination therapies with teclistamab exhibited a superior overall response rate vs teclistamab monotherapy in relapsed/refractory multiple myeloma.

Teclistamab Shows Sustained Efficacy in R/R Multiple Myeloma

Roman Fabbricatore
May 30th 2025
Article

Combination therapies with teclistamab exhibited a superior overall response rate vs teclistamab monotherapy in relapsed/refractory multiple myeloma.


Ivonescimab plus chemotherapy reduced the risk of disease progression or death by 48% vs chemotherapy alone in patients with EGFR-mutant NSCLC.

Ivonescimab Combo Shows Meaningful PFS Improvement in EGFR-Mutant NSCLC

Roman Fabbricatore
May 30th 2025
Article

Ivonescimab plus chemotherapy reduced the risk of disease progression or death by 48% vs chemotherapy alone in patients with EGFR-mutant NSCLC.

Related Content
Advertisement

At a median time to response of 1 month, isatuximab elicited a median duration of response of 10.3 months in patients with multiple myeloma.

Isatuximab Shows Efficacy, Acceptable Safety Across Multiple Myeloma Trials

Roman Fabbricatore
May 30th 2025
Article

At a median time to response of 1 month, isatuximab elicited a median duration of response of 10.3 months in patients with multiple myeloma.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Rhenium Obisbemeda Improves Survival in Recurrent Glioblastoma

Rhenium Obisbemeda Improves Survival in Recurrent Glioblastoma

Ariana Pelosci
May 30th 2025
Article

Andrew Brenner, MD, PhD, discussed rhenium obisbemeda and results from the ReSPECT-GBM trial for patients with glioblastoma.


Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Viviana Cortiana, MS4;Yan Leyfman, MD
May 19th 2025
Podcast

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.


Combination therapies with teclistamab exhibited a superior overall response rate vs teclistamab monotherapy in relapsed/refractory multiple myeloma.

Teclistamab Shows Sustained Efficacy in R/R Multiple Myeloma

Roman Fabbricatore
May 30th 2025
Article

Combination therapies with teclistamab exhibited a superior overall response rate vs teclistamab monotherapy in relapsed/refractory multiple myeloma.


Ivonescimab plus chemotherapy reduced the risk of disease progression or death by 48% vs chemotherapy alone in patients with EGFR-mutant NSCLC.

Ivonescimab Combo Shows Meaningful PFS Improvement in EGFR-Mutant NSCLC

Roman Fabbricatore
May 30th 2025
Article

Ivonescimab plus chemotherapy reduced the risk of disease progression or death by 48% vs chemotherapy alone in patients with EGFR-mutant NSCLC.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.